Someone had early access to the filing! Hehehe
$Redhill Biopharma (RDHL.US)$ RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on August 1, 2024, the publication of positive Phase 3 study data for RHB-104 in the treatment of Crohn's disease. The study, which included 331 patients and was conducted across over 100 sites globally, demonstrated a 64% increase in efficacy when RHB-104 was added to the standard of care compared to the standard of care alone. The primary endpoint of clinical remission at week 26 was achieved by 36.7% of patients treated with RHB-104 versus 22.4% of those receiving a placebo, with a safety profile similar to placebo. The study's lead investigator, Dr. David Y. Graham, highlighted the potential of RHB-104 as an effective treatment for Crohn's disease, which could serve as an add-on therapy for patients not responding to current treatments. The Crohn's disease market was valued at over $13 billion in 2023. RedHill's CEO, Dror Ben-Asher, expressed the company's commitment to advancing the development of RHB-104 and exploring partnership models to bring this treatment to market
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
Salmon Klein : 所以公司没有新的资金...我以为私人发行人是公司收到资金的时候
Trytosaveabit 楼主 Salmon Klein : 如果我没记错的话，那是几天前的事了吗？这份文件是今天早上提交的